Positive pancreatic cancer data boosts Oncolytics' Reolysin
This article was originally published in Scrip
Executive Summary
Oncolytics Biotech has once again generated positive Phase II results with its anticancer therapeutic, Reolysin, this time in advanced pancreatic cancer.